04:14 AM EDT, 10/07/2025 (MT Newswires) -- Mesoblast (MESO) said late Monday that Ryoncil sales generated $21.9 million in gross revenue for the quarter through Sept. 30, up 66% sequentially.

Ryoncil is the first mesenchymal stromal cell therapy approved by the US Food and Drug Administration for any indication, and the only approved treatment for children under 12 with steroid-refractory acute graft-versus-host disease, according to the company.